<?xml version='1.0' encoding='UTF-8' ?>
<ec-patent-document file='EC_SP17073650_20180228.xml' country='EC' doc-number='SP17073650' kind='A' date-published='20180228' lang='ES' date-produced='20190116'>
<bibliographic-data id='bibl' doc-number='SP17073650' country='EC' lang='es'>
<publication-reference><document-id ><country>EC</country><doc-number>SP17073650</doc-number><kind>A</kind><date>20180228</date></document-id></publication-reference>
<classification-ipcr><classification-ipc sequence='1'><section> </section><class> </class><subclass> </subclass><main-group> </main-group><subgroup> </subgroup><edition> </edition><ipc-version-indicator><date> </date></ipc-version-indicator><classification-level>C07K14/62,A61K38/28,C12N15/62</classification-level><symbol-position> </symbol-position><classification-value> </classification-value></classification-ipc></classification-ipcr>
<application-reference> <document-id><country>EC</country><doc-number>IEPI201773650</doc-number><date>20171106</date></document-id></application-reference>
<priority-claims>
<priority-claim sequence='1' kind='National'><doc-number>62/158,079</doc-number><date>20150507</date><country>US</country></priority-claim>
</priority-claims>
<parties><applicants>
<applicant sequence='1' designation='all' app-type='applicant'><addressbook><name>ELI LILLY AND COMPANY</name><address><street>Lilly Corporate Center, Indianapolis, Indiana 46285, Estados Unidos de America</street><country>US</country></address></addressbook></applicant>
</applicants>
<inventors>
<inventor sequence='1' designation='all'><addressbook><name>BEALS John Michael</name><address><street>c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288, Estados Unidos de America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='2' designation='all'><addressbook><name>KORYTKO Andrew Ihor</name><address><street>c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288, Estados Unidos de America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='3' designation='all'><addressbook><name>DICKINSON Craig Duane</name><address><street>c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288, Estados Unidos de America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='4' designation='all'><addressbook><name>DAY Jonathan Wesley</name><address><street>c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288, Estados Unidos de America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='5' designation='all'><addressbook><name>LAZAR Gregory Alan</name><address><street>c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288, Estados Unidos de America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='6' designation='all'><addressbook><name>BALDWIN David Bruce</name><address><street>c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288, Estados Unidos de America</street><country>US</country></address></addressbook></inventor>
</inventors><agents>
<agent sequence='1' rep-type='agent'><addressbook><name>DR. SANTIAGO GUARDERAS IZQUIERDO</name><address><street>Ave. 12 de Octubre N26-97 y Lincoln</street><country>EC</country></address></addressbook></agent>
</agents></parties>
<invention-title lang='es'>PROTEÍNAS DE FUSIÓN</invention-title>
</bibliographic-data>
<abstract lang='es'>La presente invención se refiere a proteínas de fusión que comprenden un agonista del receptor de insulina fusionado a una región Fc de IgG humana mediante el uso de un enlazante de péptido, y el uso de tales proteínas de fusión en el tratamiento de diabetes. La proteína de fusión de la presente invención tiene un perfil de acción de tiempo prolongado y es útil para proporcionar un control de glucosa basal durante un período de tiempo prolongado.</abstract>
</ec-patent-document>
